article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. 10 Since FDA approval in 1998 the ‘Little Blue Pill’ had some of the fastest prescription uptakes and sales growth of any medication, bringing in $400 million in revenue in its first quarter after launch and going on to produce annual sales of about $1.8